Cost Effectiveness Analysis of Boceprevir (BOC) Added to Pegifn/Ribavirin (P/R) Versus Pegifn/Ribavirin (Current Standard of Care) for the Treatment of Patients with Genotype 1 Chronic Hepatitis C in Greece
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.175
https://www.valueinhealthjournal.com/article/S1098-3015(13)02080-9/fulltext
Title :
Cost Effectiveness Analysis of Boceprevir (BOC) Added to Pegifn/Ribavirin (P/R) Versus Pegifn/Ribavirin (Current Standard of Care) for the Treatment of Patients with Genotype 1 Chronic Hepatitis C in Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02080-9&doi=10.1016/j.jval.2013.08.175
First page :
A352
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
161